Tag Archives: sny

Sanofi, Novo Nordisk Slide On Diabetes Headwinds

European drug giants Sanofi (SNY) and Novo Nordisk (NVO) saw their shares fall Thursday as they issued weak guidance in the face of an increasingly competitive diabetes market. Sanofi reported Q3 earnings of 1.61 euros (90 cents) a share, up 9.5% from the year-earlier quarter and 1 cent over analysts’ consensus, according to Thomson Reuters. Sales grew 9.2% to 9.59 billion euros ($10.7 billion), missing estimates by about 150 million euros. Sanofi

Amgen’s 2018 Repatha Sales Estimates Hiked 60%

The bull case for Amgen’s (AMGN) new cholesterol drug Repatha continued to be built Tuesday, as Nomura raised long-term estimates on the drug’s sales while UBS defended its optimistic thesis for both Repatha and rival drug Praluent, from Sanofi (SNY) and Regeneron (REGN). After surveying 30 cardiologists who were enthusiastic about the new anti-PCSK9 drug class, Nomura analyst Ian Somaiya hiked his 2018 estimate on Repatha to $2.1 billion from

Amgen’s Repatha OK’d With Similar Label To Praluent

The FDA approved Amgen’s (AMGN) cholesterol drug Repatha late Thursday, giving it a similar label to a recently approved rival from Regeneron (REGN) and Sanofi (SNY), but a slightly lower price. The agency said it had cleared Repatha, one of the new PCSK9 inhibitor class of drugs, for patients with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and patients with heart disease who need more